Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma
Edvan Q. Crusoé, Glaciano Ribeiro, João Tadeu D. Souto Filho, Jayr Schmidt Filho, Natalia Schutz, Milton A. F. Aranha, Abel Costa, Abrahao Hallack, Fernando V. Pericole, Juliana S. Lima, Breno Gusmão, Eduardo Flávio O. Ribeiro, Jorge P. Vaz, Rosane Bittencourt, Rafael Cunha, Danielle Ovigli, Luiza Berg, Ederson R. Mattos, Angelo Maiolino, Vania Hungria, on behalf of GBRAM British Journal of Haematology
· Wiley
· 2026-11-10
· DOI: 10.1111/bjh.70775
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Edvan Q. Crusoé, Glaciano Ribeiro, João Tadeu D. Souto Filho, Jayr Schmidt Filho, Natalia Schutz, Milton A. F. Aranha et al. Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma. // British Journal of Haematology. – 2026. – DOI: 10.1111/bjh.70775. – URL: https://onlinelibrary.wiley.com/doi/10.1111/bjh.70775?af=R
Edvan Q. Crusoé, Glaciano Ribeiro, João Tadeu D. Souto Filho, Jayr Schmidt Filho, Natalia Schutz, Milton A. F. Aranha, Abel Costa, Abrahao Hallack, Fernando V. Pericole, Juliana S. Lima, Breno Gusmão, Eduardo Flávio O. Ribeiro, Jorge P. Vaz, Rosane Bittencourt, Rafael Cunha, Danielle Ovigli, Luiza Berg, Ederson R. Mattos, Angelo Maiolino, Vania Hungria, & on behalf of GBRAM (2026). Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.70775
Edvan Q. Crusoé, et al. “Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma.” British Journal of Haematology, 2026. doi:10.1111/bjh.70775.
@article{Cruso2026,
title = {Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma},
author = {Crusoé, Edvan Q. and Ribeiro, Glaciano and Filho, João Tadeu D. Souto and Filho, Jayr Schmidt and Schutz, Natalia and Aranha, Milton A. F. and Costa, Abel and Hallack, Abrahao and Pericole, Fernando V. and Lima, Juliana S. and Gusmão, Breno and Ribeiro, Eduardo Flávio O. and Vaz, Jorge P. and Bittencourt, Rosane and Cunha, Rafael and Ovigli, Danielle and Berg, Luiza and Mattos, Ederson R. and Maiolino, Angelo and Hungria, Vania and GBRAM, on behalf of},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70775},
url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.70775?af=R}
}